Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B49
2023-506752-24-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Keytruda plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Aug 2021; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506752-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506752-24-00.